Supriya Lifescience Limited has informed that the European Directorate for the Quality of Medicines (EDQM) has granted Attestation of Inspection (EU-GMP) for Lote API Facility, Ratnagiri, Maharashtra.
The product is expected to be launched by Q4 FY23.
The approved product has an estimated market size of around US $62 million for the twelve months ending June 2022 according to IQVIA
The approved product has an estimated market size of around US$ 606 million for the twelve months ending June 2022, according to IQVIA.
This is the 142nd ANDA (including 8 tentative approvals received) out of Eugia Pharma Specialty Group (EPSG) facilities, manufacturing both oral and sterile specialty products.
he approved product has an estimated market size of US$ 83 million for the twelve months ending April 2022, according to IQVIA.
Pemetrexed for injection is indicated for the treatment of Antineoplastics (medications used to treat cancer)
The approved product has a market size of US $ 1172 million for the twelve months ending March 2022, according to IQVIA
The observations are procedural in nature and will be responded to within the stipulated time
The product will be available in 500 mg/2.5 mL and 1 g/5 mL vials
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)